Dataset from An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)

The purpose of this study is to find out whether Nivolumab will significantly improve overall survival as compared to therapy of investigator's choice in patients with recurrent or metastatic head and neck carcinoma.

本研究旨在探究相较于研究者选择的治疗方案，纳武利尤单抗（Nivolumab）能否显著改善复发或转移性头颈部癌患者的总生存期。